Neuphoria Therapeutics
NEUP
22 hedge funds and large institutions have $8.71M invested in Neuphoria Therapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
22% more capital invested
Capital invested by funds: $7.15M → $8.71M (+$1.56M)
16% more funds holding
Funds holding: 19 → 22 (+3)
4.29% more ownership
Funds ownership: 32.61% → 36.89% (+4.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$470K |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$362K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$257K |
| 4 |
Renaissance Technologies
New York
|
+$123K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$111K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$312K |
| 2 |
VF
Virtu Financial
New York
|
-$49K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$960 |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$822 |
NEUP Hedge Fund Activity: Q2 2026 in Review
22 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q2 2026, worth a combined $8.71M — up 22% from $7.15M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NEUP positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $470K. The largest seller was Squadron Capital Management, exiting entirely with an estimated $312K sold.
- 22 institutional investors held Neuphoria Therapeutics (NEUP) as of Q2 2026, up from 19 in Q1 2026.
- Funds reported $8.71M of Neuphoria Therapeutics stock for Q2 2026, up 22% quarter-over-quarter.
- 6 funds opened new Neuphoria Therapeutics positions in Q2 2026 and 3 closed out, a net change of +3 holders.
- The largest Neuphoria Therapeutics buyer in Q2 2026 was AdvisorShares Investments, an estimated $470K added.
- The largest Neuphoria Therapeutics seller in Q2 2026 was Squadron Capital Management, an estimated $312K sold.
Based on aggregated 13F filings for Q2 2026.